Home
»çÀÌÆ®¸Ê
Contact Us
Eng
¼¾ÅͼҰ³
¿¬±¸¿µ¿ª
¿¬±¸È°µ¿
¿¬±¸½ÇÀû
ÀÚ·á½Ç
°Ô½ÃÆÇ
×
¼¾ÅͼҰ³
Àλ縻
¼³¸³¸ñÀû
¿¬Çõ
Á¶Á÷µµ
Âü¿©¿¬±¸Áø
½Ã¼³ ¹× Àåºñ
¿À½Ã´Â ±æ
¿¬±¸¿µ¿ª
ÀÓ»ó¾à¹°À¯Àüü¿¬±¸ºÎ
ºÐÀھ๰À¯Àüü¿¬±¸ºÎ
¾à¹°À¯Àüü¿¬±¸ Áö¿øºÎ
¿¬±¸È°µ¿
¿¬±¸»ç¾÷
¿¬±¸°³¹ß
¿¬±¸Çù·ÂÁö¿ø
Àη¾缺
¿¬±¸½ÇÀû
ÁßÁ¡¿¬±¸ÀÚ·á
³í¹®½ÇÀû
ÇÐȸ¹ßÇ¥
ƯÇã½ÇÀû
±âŸ½ÇÀû
ÀÚ·á½Ç
º¸µµÀÚ·á
»çÁøÀÚ·á
°ü·Ã»çÀÌÆ®
°Ô½ÃÆÇ
Çà»çÀÏÁ¤
°øÁö»çÇ×
¼¾ÅͼҽÄ
Çаè¼Ò½Ä
Contact Us
Eng
³í¹®½ÇÀû
¿¬±¸½ÇÀû
ÁßÁ¡¿¬±¸ÀÚ·á
³í¹®½ÇÀû
ÇÐȸ¹ßÇ¥
ƯÇã½ÇÀû
±âŸ½ÇÀû
Áö¿ø°úÁ¦º° :
¼±ÅÃÇϱâ
BMRC
BMRC, Japan Fund
BMRC, PRCDM
BMRC, ¼ö¼Ûü
cPMTb
FRONTIER
FRONTIER, PRCDM
NRL
NRL, PRCDM
PRCDM
PRCDM, ¿¬±¸±³¼ö
RCTC
RCTC, BMRC
¿¬µµº° :
¼±ÅÃÇϱâ
2015-International
2015-Domestic
2014-International
2014-Domestic
2013-International
2013-Domestic
2012-International
2012-Domestic
2011-International
2011-Domestic
2010-International
2010-Domestic
2009-International
2009-Domestic
2008-International
2008-Domestic
2007-International
2007-Domestic
2006-International
2006-Domestic
2005-International
2005-Domestic
2004-International
2004-Domestic
2003-International
2003-Domestic
¸ðµÎº¸±â
·
Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park JK, Ghim JL, Kim EY, Cho YS, Babaoglu MO, Shin JG
Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research(cPMTb)
Br J Clin Pharmacol. 88(3):1159-1169 / 2022.03 [
LINK
]
·
Abed AF, Jarrar YB, Al-Ameer HJ, Al-Awaida W, Lee SJ
The Protective Effect of Metformin against Oxandrolone-Induced Infertility in Male Rats(cPMTb)
Curr Pharm Des. 28(4):324-330 / 2022.02 [
LINK
]
·
Jarrar YB, Jarrar O, Abaalkhail SJ, Kalloush HM, Naser W, Zihlif M, Shhab MA, Madani AE, Jamous Y, Lee SJ
Molecular toxicological alterations in the mouse hearts induced by sub-chronic thiazolidinedione drugs administration(cPMTb)
Fundam Clin Pharmacol. 36(1):143-149 / 2022.02 [
LINK
]
·
Jarrar Y, Lee SJ
Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates(cPMTb)
J Pers Med. 12(1):104 / 2022.01 [
LINK
]
·
Cho YS, Bae KS, Choi SC, Cho JM, Lim HS
Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis(cPMTb)
Clin Ther. 44(1):67-80.e1 / 2022.01 [
LINK
]
·
Pham VH, Nguyen VL, Jung HE, Cho YS, Shin JG
The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population(cPMTb)
BMC Med Genomics 3;15(1):3 / 2022.01 [
LINK
]
·
Long NP, Heo DY, Park SO, Yen NTH, Cho YS, Shin JG, Oh JY, Kim DH
Molecular perturbations in pulmonary tuberculosis patients identified by pathway-level analysis of plasma metabolic features(cPMTb)
PLoS One.24;17(1):e0262545 / 2022.01 [
LINK
]
·
Cho YS, Bae KS, Choi SC, Cho JM, Lim HS
Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis(cPMTb)
Clin Ther. 44(1):67-80.e1 / 2022.01 [
LINK
]
·
Long NP, Phat NK, Yen NTH, Park SO, Park YM, Cho YS, Shin JG
A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction(cPMTb)
Tuberculosis (Edinb). 131:102138 / 2021.12 [
LINK
]
·
Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park YM, Choi YK, Phuong NTT, Shin JG
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis(cPMTb)
J Clin Pharmacol. 61(12):1567-1578 / 2021.12 [
LINK
]
1
2
3
4
5
6
7
8
9
10
[Next]
Á¦¸ñ
ÀúÀÚ¸í
Áö¿ø°úÁ¦